IGF1R

I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase).

Figitumumab (CP-751871) is an effective fully human monoclonal antibody against insulin-like growth factor 1 receptor (IGF1R). Figitumumab can block the binding of IGF1 to IGF1R, with an IC50 of 1.8 nM.

Ganitumab (AMG 479) is a recombinant human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes mouse IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction between mouse IGF1R and IGF1/IGF2. Ganitumab can be used for cancer research.

Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor 1 receptor) antibody. Robatumumab has anti-tumor activity and anti-cancer cell proliferation activity. Robatumumab can be used for research on osteosarcoma and Ewing's sarcoma.

Teprotumumab is a human monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R). Teprotumumab binds to the ligand-binding domain of the extracellular alpha subunit of IGF-1R. It inhibits the actions of TSH and IGF-1 in fibroblasts. Teprotumumab reduces the expression of IL-6 and IL-8, which are dependent on TSH, as well as phosphorylation of Akt. It can be used for research related to thyroid-associated eye disease.

Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant humanized monoclonal antibody that targets the IGF ligands IGF1 and IGF2. Xentuzumab inhibits the growth-promoting signals of both IGF1 and IGF2, suppressing the activation of AKT.

Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1.

Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody.

CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively).

Selective IGF-1R inhibitor